Welcome to our dedicated page for Minerva Neurosci news (Ticker: NERV), a resource for investors and traders seeking the latest updates and insights on Minerva Neurosci stock.
Minerva Neurosciences, Inc. reports clinical and corporate updates as a clinical-stage biopharmaceutical company developing therapies for central nervous system disorders. Company news centers on roluperidone, its product candidate for negative symptoms of schizophrenia, including confirmatory Phase 3 activity, clinical safety data, pharmacokinetic and pharmacodynamic findings, and discussions related to trial design.
Recurring updates also cover financial results, research and development spending, private financing tied to the roluperidone program, investor and scientific conference participation, and governance changes. Minerva’s disclosures are focused on the development path for CNS product candidates rather than commercial product sales.
Minerva Neurosciences (NASDAQ: NERV) will release its third-quarter 2020 financial results on November 2, 2020, at 8:30 a.m. ET. The conference call will provide business updates and insights into their clinical-stage biopharmaceutical developments targeting central nervous system disorders. Key products in their portfolio include roluperidone for schizophrenia and MIN-301 for Parkinson’s disease. Investors can access the call by dialing the provided numbers and a webcast will be available for later viewing.
Minerva Neurosciences, a clinical-stage biopharmaceutical company, will participate in Citi's 15th Annual BioPharma Virtual Conference on September 9, 2020, at 1:30 p.m. ET. The panel discussion focuses on "Emerging Therapies for Psychiatric Disorders." Investors can access the presentation live and on-demand via the company's website. Minerva’s product pipeline includes roluperidone for schizophrenia and seltorexant for insomnia, with additional projects targeting Parkinson’s disease.
Minerva Neurosciences, a clinical-stage biopharmaceutical firm focused on CNS disorders, will present at the JMP Securities CNS Forum on August 19, 2020, at 10:30 a.m. ET. This virtual event will be accessible via a webcast on the company's investor relations website. Minerva's product pipeline includes roluperidone for schizophrenia, seltorexant for insomnia and MDD, and MIN-301 for Parkinson's disease. The stock trades on NASDAQ under the symbol NERV.
Minerva Neurosciences (NASDAQ: NERV) reported Q2 2020 financial results, highlighting a net income of $29.5 million, or $0.75 per share, a turnaround from a loss of $12.5 million in the same period last year. The company recognized $41.2 million in collaborative revenue following its decision to opt out of the seltorexant agreement with Janssen. R&D expenses dropped to $5.8 million from $8.3 million year-over-year. However, the Phase 3 trial for roluperidone did not meet its primary endpoints, though some statistically significant improvements were observed.
Minerva Neurosciences (NASDAQ: NERV) announced a webcast on June 5, 2020, to present additional results from its Phase 3 trial focusing on negative symptoms of schizophrenia. This event replaces a previously scheduled session and will feature key opinion leaders who will discuss the findings. The company continues to develop roluperidone, a candidate for schizophrenia, alongside other compounds for insomnia and Parkinson's disease. Investors can participate via a conference call or listen to the live webcast, with an archived version available for 90 days.
Minerva Neurosciences announced that the Phase 3 trial for roluperidone to treat negative symptoms of schizophrenia did not meet its primary endpoint, which was the reduction in the PANSS Marder Negative Symptoms Factor Score. Both the 32 mg and 64 mg doses showed no significant difference from placebo at Week 12. However, the 64 mg dose demonstrated statistically significant effects at earlier time points, indicating potential efficacy. The drug was generally well tolerated, with adverse events comparable to placebo. The company plans to consult with the FDA regarding further development.
Summary not available.
Summary not available.